September 25, 2026

FDA monthly preview: Key October decisions to watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

September 24, 2026

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

MDSpire News

September 21, 2026

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

MDSpire News

September 10, 2026

Mild metabolic profile may mask MASLD risk

Five reproducible MASLD subtypes showed distinct genetic profiles and patterns of metabolic comorbidity and disease progression.

MDSpire News

September 09, 2026

FDA expands sevabertinib approval in NSCLC

SOHO-01 data showed a 75% confirmed objective response rate among 69 patients without previous systemic therapy.

MDSpire News

September 09, 2026

Inflammatory signatures may distinguish dental caries

Combining IL-17 with TNF-alpha showed strong discrimination between carious lesions and healthy controls, but performance was more modest against gingival inflammation.

MDSpire News

September 08, 2026

FDA approves serial liquid biopsy testing

In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.

MDSpire News

September 04, 2026

Inside the hip osteoarthritis microbiome

Investigators compared intra-articular microbial profiles and predicted metabolic pathways in patients with hip osteoarthritis and nonarthritic controls.

MDSpire News

September 02, 2026

Medical Oddities: Dogs share our mortality markers

The bond with dogs runs deeper, the brain enjoys a good sweat, love on screen gets real, and tea carries a little more weight.

MDSpire News

September 01, 2026

FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.

MDSpire News